Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 226 Breast Neoplasms 201 Lung Neoplasms 188 Glioblastoma 187 Head and Neck Neoplasms 174 Prostatic Neoplasms 160 Squamous Cell Carcinoma of Head and Neck 147 Lymphoma 144 Rectal Neoplasms 128 Central Nervous System Neoplasms 114 Esophageal Neoplasms 113 Leukemia 101 Brain Neoplasms 97 Pancreatic Neoplasms 89 Precursor Cell Lymphoblastic Leukemia-Lymphoma 86 Gliosarcoma 82 Esophageal Squamous Cell Carcinoma 76 Lymphoma, Follicular 75 Sarcoma 73 Lymphoma, Large B-Cell, Diffuse 73 Uterine Cervical Neoplasms 72 Neoplasms 71 Lymphoma, Non-Hodgkin 70 Hodgkin Disease 69 Burkitt Lymphoma 63 Glioma 60 Colorectal Neoplasms 60 Leukemia, Lymphocytic, Chronic, B-Cell 59 Astrocytoma 59 Lymphoma, Large-Cell, Immunoblastic 54

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡